Skip to main navigation Skip to search Skip to main content

DELTA 2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial

  • Jonathan A. Cook*
  • , Steven A. Julious
  • , William Sones
  • , Lisa V. Hampson
  • , Catherine Hewitt
  • , Jesse A. Berlin
  • , Deborah Ashby
  • , Richard Emsley
  • , Dean A. Fergusson
  • , Stephen J. Walters
  • , Edward C.F. Wilson
  • , Graeme MacLennan
  • , Nigel Stallard
  • , Joanne C. Rothwell
  • , Martin Bland
  • , Louise Brown
  • , Craig R. Ramsay
  • , Andrew Cook
  • , David Armstrong
  • , Doug Altman
  • Luke D. Vale
*Corresponding author for this work
  • University of Oxford
  • University of Sheffield
  • Novartis
  • Lancaster University
  • University of York
  • Johnson & Johnson
  • Imperial College London
  • King's College London
  • Ottawa Hospital Research Institute
  • University of Cambridge
  • University of Warwick
  • Medical Research Council
  • University of Southampton
  • Newcastle University

Research output: Contribution to journal › Article › peer-review

20 Downloads (Pure)

Abstract

Randomised controlled trials are considered to be the best method to assess comparative clinical efficacy and effectiveness, and can be a key source of data for estimating cost effectiveness. Central to the design of a randomised controlled trial is an a priori sample size calculation, which ensures that the study has a high probability of achieving its prespecified main objective. Beyond pure statistical or scientific concerns, it is ethically imperative that an appropriate number of study participants be recruited, to avoid imposing the burdens of a clinical trial on more patients than necessary. The scientific concern is satisfied and the ethical imperative is further addressed by the specification of a target difference between treatments that is considered realistic or important by one or more key stakeholder groups. The sample size calculation ensures that the trial will have the required statistical power to identify whether a difference of a particular magnitude exists. In this article, the key messages from the DELTA 2 guidance on determining the target difference and sample size calculation for a randomised controlled trial are presented. Recommendations for the subsequent reporting of the sample size calculation are also provided.

Original languageEnglish
Article numberk3750
JournalBMJ
Volume363
DOIs
Publication statusPublished - 5 Nov 2018

Bibliographical note

Funding: Funding for this work was received from the MRC-NIHR UK Methodology Research Programme in response to an open commissioned call for an effect size methodology state-of-the-art workshop. The Health Services Research Unit, Institute of Applied Health Sciences (University of Aberdeen), is core funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates. The funders had no involvement in study design, collection, analysis, and interpretation of data; reporting; or the decision to publish.

Funding

1Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Nuffield Orthopaedic Centre, Oxford OX3 7LD, UK 2Medical Statistics Group, ScHARR, University of Sheffield, Sheffield, UK 3Statistical Methodology and Consulting, Novartis, Basel, Switzerland 4Department of Mathematics and Statistics, Lancaster University, Lancaster, UK 5Department of Health Sciences, University of York, Heslington, York, UK 6Johnson & Johnson, Titusville, NJ, USA 7Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK 8Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK 9Clinical Epidemiology Programme, Ottawa Hospital Research Institute, Ottawa, ON, Canada 10Cambridge Centre for Health Services Research and Cambridge Clinical Trials Unit, University of Cambridge, Institute of Public Health, Cambridge, UK 11Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK 12Warwick Medical School—Statistics and Epidemiology, University of Warwick, Coventry, UK 13MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK 14Health Services Research Unit, University of Aberdeen, Aberdeen, UK 15Wessex Institute, University of Southampton, Southampton, UK 16School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK 17Health Economics Group, Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK This paper summarised key findings of the new guidance produced by the DELTA2 study, commissioned by the UK Medical Research Council (MRC)/National Institute for Health Research (NIHR) Methodology Research Programme, in response to an open commissioned call to organise a workshop on this topic in order to produce guidance. The authors are all researchers who have been involved in randomised trials of varying types, with most involved for more than 10 years; they have varying backgrounds and have worked in various clinical areas and on both academic and industry funded studies. The members of the original DELTA (Difference ELicitation in TriAls)2 group were Jonathan Cook, Doug Altman, Jesse Berlin, Martin Bland, Richard Emsley, Dean Fergusson, Lisa Hampson, Catherine Hewitt, Craig Ramsay, Joanne Rothwell, Robert Smith, William Sones, Luke Vale, Stephen Walters, and Steven Julious. As part of the guidance development process, the two day workshop held in Oxford in September 2016 included the following participants: Doug Altman, David Armstrong, Deborah Ashby, Martin Bland, Andrew Cook, Jonathan Cook, David Crosby, Richard Emsley, Dean Fergusson, Andrew Grieve, Lisa Hampson, Catherine Hewitt, Steven Julious, Graeme MacLennan, Tim Maughan, Jon Nicholl, José Pinheiro, Craig Ramsay, Joanne Rothwell, William Sones, Nigel Stallard, Luke Vale, Stephen Walters, and Ed Wilson. We thank the participants in the Delphi study and the one-off engagement sessions with various groups, including the attendees to the Society for Clinical Trials, Statisticians in the Pharmaceutical Industry, and Joint Statistical Meeting conference sessions, along with the other workshop participants who kindly provided helpful input and comments on the scope and content of this document; Robert Smith for his role as a member of the public who provided helpful public perspective and input in the workshop and also development and revision of the guidance document; Stefano Vezzoli for in-depth comments that helped to refine this document; and the MRC Methodology Research Programme advisory panel that commissioned the study and provided helpful feedback on a draft version. Contributors: JAC and SAJ conceived of the idea and drafted the initial version of the manuscript. WS, LVH, CH, JAB, DAs, RE, DAF, SJW, ECFW, GM, NS, JCR, MB, LB, CRR, AC, DAr, DAl, and LDV contributed to the development of the guidance and commented on the draft manuscript. All authors have read and approved the final version. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Funding: Funding for this work was received from the MRC-NIHR UK Methodology Research Programme in response to an open commissioned call for an effect size methodology state-of-the-art workshop. The Health Services Research Unit, Institute of Applied Health Sciences (University of Aberdeen), is core funded by the Chief Scientist Office of the Scottish Government Health and Social Care Directorates. The funders had no involvement in study design, collection, analysis, and interpretation of data; reporting; or the decision to publish. disclosure form at http://www.icmje.org/conflicts-of-interest/ and declare: support from the MRC-NIHR UK Methodology Research Programme for the submitted work; JAB is employee of Johnson & Johnson and holds shares in this company; LVH is an employee of Novartis; all the other authors have been involved in design and conducting randomised trials through their roles; no other financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work. Ethical approval: Ethics approval for the Delphi study, which is part of the DELTA2 project, was sought and received from the University of Oxford’s medical sciences interdivisional research ethics committee (IDREC - R46815/RE001). Informed consent was obtained for all participants in the Delphi study.

Fingerprint

Dive into the research topics of 'DELTA 2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial'. Together they form a unique fingerprint.

Cite this